Single daily dose of cyclosporine in patients with primary glomerulonephritis and nephrotic syndrome

Benefits of Once-Daily Administration of Cyclosporine A for Children with Steroid-Dependent, Relapsing Nephrotic Syndrome

“…Its efficacy and safety when administered once daily [singledaily dose (SDD) protocol] under peak or 2-hour post-dosing blood level monitoring (C 2 ) in patients with SDRNS has also been reported (Tanaka et al 2004;Nakahata et al 2005;Rasche et al 2007;Takeda et al 2007). However, there is no consensus as to whether the SDD protocol of CsA is as effective as the TDD protocol in children with SDRNS.…”

Advances in the treatment of refractory nephrotic syndrome in children

“…Li et al [52] included seven studies to evaluate the efficacy and safety of Cs A in SRNS, complete remission was higher in the Cs A group, albumin levels were elevated, serum creatinine and serum cholesterol levels were lower, gingival hyperplasia was higher in the Cs A group than in the control group, and the incidence of infection and hypertension was similar to the control group, Cs A is a safe and effective agent for the treatment of SRNS.Cs A may cause nephrotoxicity when this side effect is more pronounced when it is used for a longer period of time, at higher doses, in the presence of hypertension or with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers [53] , and blood Cs A levels greater than 200 ng/ml or elevated basal serum creatinine may also be responsible for nephrotoxicity [54] . In order to reduce adverse effects and control Cs A blood concentrations, Shen Lihong et al [55] concluded that the older the patient, the higher the creatinine and urea levels, and the lower the hemoglobin, the lower the Cs A dosage should be reduced, which has some limitations with the age of their patients >14 years and the lack of data related to the patients' body mass index.In summary, the advantages and disadvantages associated with each drug are shown in Table 1.…”

A Case of Membranous Nephropathy with Primary Biliary Cirrhosis and Cyclosporine-induced Remission

“…2). CsA was administered once daily (3,4), and the dose was adjusted by monitoring the C2 levels (i.e., blood concentration at 2 hours after CsA administration), with a target CsA C2 level set at 600-800 ng/mL; the actual C2 level was 775 ± 278 ng/mL (mean ± SD, n=17). The serum creatinine levels remained unchanged during the treatment period (1.0 mg/ dL).…”